1
|
Kaneria NS, Tuleu C, Ernest T. Opportunities for enteral drug delivery for neonates, infants and toddlers: a critical exploration. Expert Opin Drug Deliv 2022; 19:475-519. [PMID: 35404191 DOI: 10.1080/17425247.2022.2064449] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION The field of neonatal, infant and toddler pharmaceutical development is constantly improving, however a lag still remains in comparison to older children and adults. Their rapid anatomical, physiological and behavioural developmental rates pose extra challenges in diagnosing, treating, or preventing their disease. In turn, this brings complexity in formulating truly age-appropriate medicinal products that suit this heterogeneous paediatric subset. Progress in the availability of such products has ensued following the introduction of the 2007 European Union Paediatric Regulation, and in recent years, oral multiparticulate and dispersible solid formulations have gained interest alongside liquid formulations. However, the need is still great for dosage forms that do not compromise on pharmaceutical efficacy, safety and global accessibility in those aged under 2. AREAS COVERED This article highlights some of the formulation challenges correlated with this age group and critically explores recent solid age-appropriate formulations and their administration devices for enteral drug delivery. EXPERT OPINION There are many formulation requirements to consider when formulating drug products for children aged under 2. Efforts are required into understanding acceptability in this age group and of their carers, and whether innovation or optimisation is required, to help guide formulators towards optimal approaches without impacting access.
Collapse
Affiliation(s)
- Nicole Sheena Kaneria
- University College London, School of Pharmacy, 29-39 Brunswick Square, Bloomsbury, London, WC1N 1AX UK
| | - Catherine Tuleu
- University College London, School of Pharmacy, 29-39 Brunswick Square, Bloomsbury, London, WC1N 1AX UK
| | - Terry Ernest
- GlaxoSmithKline, New Frontiers Science Park, Third Avenue Essex, Harlow, CM19 5AW UK.,GlaxoSmithKline, Hertfordshire, Park Road, Ware, UK, SG12 0DP
| |
Collapse
|
2
|
Nguyen PV, Aubry C, Boudaoud N, Gaubert A, Langlois MH, Marchivie M, Gaudin K, Arpin C, Barthélémy P, Kauss T. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022; 14:299. [PMID: 35214036 PMCID: PMC8876242 DOI: 10.3390/pharmaceutics14020299] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 01/20/2022] [Accepted: 01/25/2022] [Indexed: 02/06/2023] Open
Abstract
Antibiotic resistance has become a major issue in the global healthcare system, notably in the case of Gram-negative bacteria. Recent advances in technology with oligonucleotides have an enormous potential for tackling this problem, providing their efficient intrabacterial delivery. The current work aimed to apply this strategy by using a novel nanoformulation consisting of DOTAU, a nucleolipid carrier, in an attempt to simultaneously deliver antibiotic and anti-resistance oligonucleotides. Ceftriaxone, a third-generation cephalosporin, was formulated with DOTAU to form an ion pair, and was then nanoprecipitated. The obtained solid nanocapsules were characterized using FT-IR, XRD, HPLC, TEM and DLS techniques and further functionalized by the anti-resistance ONα sequence. To obtain an optimal anti-resistance activity and encapsulation yield, both the formulation protocol and the concentration of ONα were optimized. As a result, monodispersed negatively charged nanoparticles of CFX-DOTAU-ONα with a molar ratio of 10:24:1 were obtained. The minimum inhibitory concentration of these nanoparticles on the resistant Escherichia coli strain was significantly reduced (by 75%) in comparison with that of non-vectorized ONα. All aforementioned results reveal that our nanoformulation can be considered as an efficient and relevant strategy for oligonucleotide intrabacterial delivery in the fight against antibiotic resistance.
Collapse
Affiliation(s)
- Phuoc Vinh Nguyen
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Clémentine Aubry
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Narimane Boudaoud
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Alexandra Gaubert
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Marie-Hélène Langlois
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Mathieu Marchivie
- UMR 5026, University of Bordeaux, CNRS, Bordeaux-INP, ICMCB, 87 Avenue du Dr Albert Schweitzer, CEDEX, 33608 Pessac, France;
| | - Karen Gaudin
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Corinne Arpin
- MFP, CNRS 5234, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France;
| | - Philippe Barthélémy
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| | - Tina Kauss
- ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France; (P.V.N.); (C.A.); (N.B.); (A.G.); (M.-H.L.); (K.G.); (P.B.)
| |
Collapse
|
3
|
Hanning SM, Matiz S, Krasser K, Orlu M, Dodoo C, Gaisford S, Tuleu C. Characterisation of rectal amoxicillin (RAMOX) for the treatment of pneumonia in children. Drug Deliv Transl Res 2021; 11:944-955. [PMID: 32588280 PMCID: PMC8096741 DOI: 10.1007/s13346-020-00804-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Access to medicines, including their availability and affordability, is a major public health challenge worldwide. This research aimed to characterise rectal formulations containing amoxicillin for the treatment of pneumonia in children under five, as an accessible alternative to existing formulations. Lipophilic Suppocire (S-NA15) and hydrophilic polyethylene glycol (PEG; 80% PEG 1500 and 20% PEG 4000, w/w) suppositories containing 250 mg amoxicillin were prepared. Hardness, apparent viscosity, uniformity of mass, uniformity of content, disintegration and dissolution time were determined. Irritation potential was screened using a slug mucosal assay and antibacterial efficacy against Staphylococcus aureus determined by isothermal microcalorimetry. Both lipophilic and hydrophilic formulations met the European Pharmacopoeia standards for suppositories when tested in vitro. They disintegrated within 30 min with rapid amoxicillin release profiles (98.6 ± 0.9%, 94.9 ± 1.2% over 30 min, respectively). Over-encapsulation of S-NA15 suppositories with hydroxypropyl methylcellulose shells slowed drug release and improved stability over 2 months. S-NA15 suppositories were classified as non-irritant and PEG suppositories only mildly irritant. Antibacterial efficacy of formulations was equivalent to amoxicillin alone. Both PEG and over-encapsulated S-NA15 rectal formulations developed in the present work have shown promise based on pre-clinical screening, and further development is justified to develop a product with commercial potential.
Collapse
Affiliation(s)
- Sara M Hanning
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
- School of Pharmacy, The University of Auckland, 85 Park Road, Auckland, New Zealand
| | - Silvia Matiz
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
| | - Katharina Krasser
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
| | - Mine Orlu
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
| | - Cornelius Dodoo
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
- School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana
| | - Simon Gaisford
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
| | - Catherine Tuleu
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
| |
Collapse
|
4
|
O'Brien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G, Pertile M, Nunn A, Tuleu C. Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine. Int J Mol Sci 2019; 20:E2688. [PMID: 31159216 PMCID: PMC6600135 DOI: 10.3390/ijms20112688] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 05/17/2019] [Accepted: 05/24/2019] [Indexed: 12/12/2022] Open
Abstract
The development of age-appropriate formulations should focus on dosage forms that can deliver variable yet accurate doses that are safe and acceptable to the child, are matched to his/her development and ability, and avoid medication errors. However, in the past decade, the medication needs of neonates have largely been neglected. The aim of this review is to expand on what differentiates the needs of preterm and term neonates from those of the older paediatric subsets, in terms of environment of care, ability to measure and administer the dose (from the perspective of the patient and carer, the routes of administration, the device and the product), neonatal biopharmaceutics and regulatory challenges. This review offers insight into those challenges posed by the formulation of medicinal products for neonatal patients in order to support the development of clinically relevant products.
Collapse
Affiliation(s)
- Fiona O'Brien
- School of Pharmacy, Royal College of Surgeons in Ireland, 111 St Stephens Green Dublin 2, Ireland.
| | | | - Kamelia Krysiak
- School of Pharmacy, Royal College of Surgeons in Ireland, 111 St Stephens Green Dublin 2, Ireland.
| | - Hannah Batchelor
- College of Medical and Dental Sciences, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK.
| | - Peter Field
- University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK.
| | - Grazia Caivano
- Chiesi Farmaceutici S.p.A. Largo Francesco Belloli 11/A-43122 Parma, Italy.
| | - Marisa Pertile
- Chiesi Farmaceutici S.p.A. Largo Francesco Belloli 11/A-43122 Parma, Italy.
| | - Anthony Nunn
- Department of Women's and Children's Health, University of Liverpool, Liverpool Women's Hospital, Liverpool L8 7SS, UK.
| | - Catherine Tuleu
- University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK.
| |
Collapse
|